SUBSCRIBE
SUBSCRIBE
News   Drug Development

Osiris Therapeutics, Inc. Reports Interim Data for COPD Stem Cell Study; Drug Fails to Improve Lung Function

June 24, 2009 | 
1 min read

Bookmark and Share

Reuters -- Osiris Therapeutics said on Tuesday that interim data from a mid-stage trial show that its experimental adult stem cell treatment did not improve lung function in patients with chronic obstructive pulmonary disorder.

Clinical research Phase II Phase III
Osiris Therapeutics, Inc.
MORE ON THIS TOPIC
Mental health, illness ,brain development ,medical treatment concept, messy lines of thinks in human head , vector illustration
Neurodegenerative disease
UniQure Clears Path to Accelerated Approval for Huntington’s Gene Therapy
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
GSK's headquarters office building in Poznan, Poland
Cancer
GSK Touts 42% Survival Benefit for Blenrep in Multiple Myeloma, Strengthening Bid for Market Return
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
A player checkmates the king, target in the background, chess game and strategy concept, vintage style poster
CAR-T
Gilead/Arcellx’s Anito-Cel’s Differentiated Safety Profile Challenges J&J/Legend’s Carvykti
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: An Eli Lilly Research Laboratories sign/
Cancer
Lilly’s Strong Phase III Survival Data for Jaypirca Clouded by Deaths
December 10, 2024
 · 
2 min read
 · 
Tristan Manalac